|
 |
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10 |
 |
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10 |
 |
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10 |
 |
Revisions to TRIUMEQ and DOVATO labeling
FDA | March 2, 2021
|
 |
Op-ed: Six Protected Classes and Protecting People with HIV
plus | February 26, 2021
|
 |
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare | February 24, 2021
|
 |
Ask the Doctors: New HIV treatment administered monthly
Lompoc Record | February 18, 2021
|
 |
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection
ViiV Healthcare | January 21, 2021
|
 |
MAT Provides Patients with More Transparency Around Medicine Costs
ADAP Advocacy Association | January 21, 2021
Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).
|
 |
Tivicay approved in Europe in new dispersible tablet for children with HIV
pharmaphorum | January 14, 2021
|
 |
Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries
Infectious Disease Advisor | January 11, 2021
|
 |
Many health plans now must cover full cost of expensive HIV prevention drugs
Duluth News Tribune | January 10, 2021
|
|
|
|